Referanser

 

1 - Johnson M et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virological failures. AIDS. 2006;20:711-18.

 

2 - Zucker SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-76.

 

3 - Berk PD, et al. Bilirubin metabolism and the hyperbilirubinemias. In Braunwald E et al, Eds. Harrison´s principles of internal medicine. 15th ed. New York 2001:1715-20.

 

4 - Atazanavir Briefing Document, May 2003. Available online at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_BristolMyersSquibb-Atazanavir.pdf. Bristol-Myers Squibb Comany, Princeton, NJ 08543, pp 38.

 

5 - Moyle G et al. The assessing patients’ preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14 (Suppl1):34-6.

 

6 - Kivexa® SPC.

 

7 - Truvada® SPC.

 

8  - O´Brien ME. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-14.